Clearance Summary
ONLINE DAT Benzodiazepines II received FDA 510(k) clearance under submission number K221765, sponsored by Roche Diagnostics. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Toxicology review panel. The statutory decision date of record is 2022-12-23.
- Submission: K221765
- Applicant / Sponsor: Roche Diagnostics
- Clearance pathway: Traditional
- Review panel: Clinical Toxicology
- Device class: Class II
- Regulation citation: 21 CFR 862.3170
- Decision date: 2022-12-23
Classification & Regulation
This clearance is catalogued under FDA product code JXM and 21 CFR 862.3170, within the Clinical Toxicology review panel as a Class II device.